Skip to main content

Black Diamond Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

BDTX$1.60-14.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Black Diamond Therapeutics, Inc. Condensed Consolidated Statements of Stockholders' Equity (Unaudited)(in thousands, except share data)
Common stock · Additionalpaid-in capital · Accumulated other comprehensive income (loss) · Accumulated deficit · Totalstockholders’equity
Shares · Par Value
BALANCE - December 31, 202351,645,557$7$534,187$(27)$(417,431)$116,736
Issuance of common stock, net of issuance costs800,000—4,000——4,000
Exercise of common stock options47,741—86——86
Vesting of restricted stock units1,250—————
Issuance of common stock related to ESPP26,659—64——64
Stock-based compensation6,419—1,713——1,713
Unrealized gain (loss) on investments———(68)—(68)
Net loss————(18,225)(18,225)
BALANCE - March 31, 202452,527,6267540,050(95)(435,656)104,306
BALANCE - December 31, 202456,644,655$7$570,361$24$(487,107)$83,285
Issuance of common stock related to ESPP17,567—32——32
Stock-based compensation14,494—1,700——1,700
Unrealized gain (loss) on investments———(43)—(43)
Net loss————56,54256,542
BALANCE - March 31, 202556,676,716$7$572,093$(19)$(430,565)$141,516
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.